Supernus Pharmaceuticals, Inc. (0LB2)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 40.56 |
|---|---|
| 52-week range | 37.96 – 59.74 |
| Return, 1 month / 3 months | −5.9% / −14.9% |
| Return, 1 year / 3 years | – / – |
| Trend | Below its 200-day average |
| RSI (14) | 44 |
| Volatility (1 year) | 39.2% |
| Worst drawdown (1 year) | -32.2% |
| Average daily value traded | 0.01M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Supernus Pharmaceuticals is a pharmaceutical company that develops and commercialises medicines for central nervous system conditions. Its products treat epilepsy and attention deficit hyperactivity disorder, and it also markets treatments for migraine and movement disorders. The company serves patients and prescribers through neurologists, psychiatrists and other specialists, and it carries out its own research and development alongside its commercial operations. Supernus Pharmaceuticals is based in Rockville, Maryland, in the United States.
On this site Supernus Pharmaceuticals, Inc. appears as a stock on the London Exchange (UK), code 0LB2, with prices in US dollars (USD). Dividend data for this stock is not available yet. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Supernus Pharmaceuticals, Inc. (0LB2) trades on the London Exchange in UK. It last closed at USD 40.56 on 23 October 2026.
Its price-based Market X-Ray is 26 out of 100 (a weak price profile), ranking 3,219 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 25 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -15.0% | ||
| From 52-week high | -27.9% | ||
| Momentum | 21 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -14.9% | ||
| 6-month return | -17.2% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 43 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.2% | ||
| Liquidity | 10 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M USD | ||
| Zero-volume days | 11.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +6.3% |
|---|---|
| 1 month | −5.9% |
| 3 months | −14.9% |
| 6 months | −17.2% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 43.63 / 47.73 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.27 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.